Metrics to compare | MBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMBXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.3x | −6.7x | −0.5x | |
PEG Ratio | −0.28 | −0.11 | 0.00 | |
Price/Book | 3.8x | 2.1x | 2.6x | |
Price / LTM Sales | - | 2.1x | 3.2x | |
Upside (Analyst Target) | 121.6% | 174.7% | 48.1% | |
Fair Value Upside | Unlock | 10.0% | 6.6% | Unlock |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.